Beta Blockers Reduce Mortality In Heart Failure Patients Wit
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Beta-blockers are recommended for heart failure (HF) patients but their benefit in the dialysis population is uncertain. Beta-blockers are heterogeneous including with respect to their removal by hemodialysis. Researchers sought to evaluate whether beta-blocker use and their dialyzability characteristics were associated with early mortality among chronic kidney disease (CKD) patients with HF who transitioned to dialysis.

In a retrospective cohort study, adults patients with CKD and HF who initiated either hemodialysis or peritoneal dialysis within an integrated health system were included.

Patients were considered treated with beta-blockers if they had a quantity of drug dispensed covering the dialysis transition date. All-cause mortality within 6 months and 1 year, or hospitalization within 6 months after transition to maintenance dialysis was assessed.

-- A total of 3,503 patients were included in the study. There were 2,115 (60.4%) patients on beta-blockers at transition.

-- Compared to non-users, the hazard ratio for all-cause mortality within 6 months was 0.79 among users of any beta-blocker, and 0.68 among users of metoprolol at transition.

-- There were no observed differences in all-cause or cardiovascular-related hospitalization.

Beta-blockers were associated with a lower rate of mortality among incident hemodialysis patients with HF. Similar associations were not observed for hospitalizations within the first 6 months following transition to dialysis, authors concluded.